Chaperone-Mediated Autophagy Degrader Services

Name: CMA-Based Degradation Technology Development
Brand: BOC Sciences

Chaperone-Mediated Autophagy (CMA)-based degradation technology is a lysosome-directed targeted protein degradation strategy designed to eliminate selected intracellular proteins by recruiting the endogenous CMA machinery. Unlike Proteolysis-Targeting Chimera (PROTAC) strategies that mainly hijack the ubiquitin-proteasome system (UPS), CMA-based degraders guide protein of interest (POI) substrates toward the lysosomal pathway, where they are recognized, unfolded, translocated, and degraded. This mechanism makes CMA-based degradation an attractive research approach for cytosolic, aggregation-prone, or proteasome-resistant proteins that are difficult to address using conventional inhibitor or UPS-dependent degradation strategies.

A typical CMA-based degrader contains three functional components: a target-binding ligand or peptide that recognizes the POI, a CMA-targeting motif (CTM) that mimics the KFERQ-like recognition sequence, and a cell-penetrating peptide (CPP) that supports intracellular delivery. After cellular entry, the degrader binds the POI to form a complex. The KFERQ-like motif is recognized by heat shock cognate 71 kDa protein (HSC70), which delivers the complex to lysosome-associated membrane protein type 2A (LAMP-2A). The substrate is then unfolded and directly translocated into the lysosomal lumen, where acidic hydrolases complete degradation.

BOC Sciences provides integrated CMA-based degradation technology development services for pharmaceutical, biotechnology, academic, and CRO research teams. Our support covers target feasibility assessment, POI ligand and peptide binder design, CTM engineering, CPP and linker optimization, degrader synthesis, cellular uptake analysis, HSC70/LAMP-2A pathway validation, lysosomal degradation assays, and iterative optimization. By combining peptide chemistry, targeted degradation biology, and mechanism-focused cellular evaluation, we help clients build CMA-based degrader programs with clearer design logic and decision-ready experimental data.

Services

BOC Sciences' Comprehensive CMA-Based Degradation Technology Development Services

Target Feasibility and CMA Compatibility Assessment
The first step in CMA-based degrader development is to determine whether the selected POI is biologically and technically suitable for CMA recruitment. BOC Sciences evaluates target localization, soluble versus aggregation-prone state, available binder information, KFERQ accessibility, lysosomal pathway context, cellular model suitability, and measurable degradation endpoints.
POI suitability assessment: evaluation of cytosolic exposure, disease relevance, conformational flexibility, aggregation tendency, and compatibility with lysosomal degradation
CMA pathway context analysis: assessment of HSC70 and LAMP-2A expression, basal lysosomal activity, stress sensitivity, and expected CMA pathway responsiveness in selected cell models
Competitive modality selection: comparison with PROTAC degradation technology development and lysosomal-based degradation technology development when multiple degradation routes are technically possible
POI-Targeting Ligand and Peptide Binder Design
A CMA-based degrader requires a target-binding module that can recognize the POI without blocking CMA recruitment, substrate unfolding, or lysosomal translocation. We support the design and screening of peptide binders, small-molecule ligands, protein-interaction motifs, and hybrid recognition modules based on target biology and available structural information.
Peptide binder discovery and optimization: design of POI-binding peptides for aggregation-prone proteins, signaling proteins, transcription-associated targets, or mutant protein species
Small-molecule ligand adaptation: evaluation of known POI ligands and derivatization sites suitable for conjugation with CTM, CPP, and linker modules
Binder validation: affinity and selectivity evaluation using binding affinity measurement, protein interaction assays, and cellular target engagement readouts
Target-binder service integration: custom support for peptide ligand for target protein development when no suitable POI-binding motif is available
CMA-Targeting Motif and CPP Engineering
CTM and CPP modules strongly influence degrader recognition, intracellular exposure, endosomal escape, and pathway specificity. BOC Sciences designs KFERQ-inspired CTM variants and CPP architectures to improve HSC70 recognition while balancing peptide stability, solubility, cell entry, and lysosome-directed degradation activity.
KFERQ-like CTM design: rational design of natural or modified CMA-recognition motifs to support HSC70 binding and LAMP-2A-dependent lysosomal targeting
CTM accessibility optimization: adjustment of CTM position, spacing, charge, and steric exposure to avoid masking by the POI-binding domain or linker
CPP selection and modification: design of cell-penetrating peptide modules to improve cellular uptake while minimizing nonspecific stress or excessive endosomal retention
Negative control design: development of CTM-mutated, CPP-modified, or binder-inactive control molecules to support mechanism interpretation
Linker Architecture and Conjugation Strategy Optimization
In CMA-based degrader design, linker geometry determines whether the POI-binding module, CTM, and CPP can function together in the correct spatial orientation. We optimize linker length, flexibility, hydrophilicity, charge distribution, and conjugation site to improve intracellular delivery, target engagement, and HSC70 accessibility.
Modular linker design: construction of PEG, alkyl, semi-rigid, peptidomimetic, and cleavable linker series for different POI and peptide architectures
Conjugation-site mapping: identification of attachment sites that preserve POI binding and expose the CTM for chaperone recognition
Structure-property balancing: optimization of molecular size, polarity, charge, solubility, and membrane interaction to improve cellular exposure
Specialized linker support: integration with linker design and optimization services for focused degrader optimization campaigns
CMA-Based Degrader Synthesis and Characterization
CMA-based degraders often contain peptide, peptidomimetic, small-molecule, and linker components within one multifunctional molecule. BOC Sciences supports customized synthesis, purification, analytical characterization, and compound panel generation for early discovery, mechanism studies, and optimization campaigns.
Peptide and conjugate synthesis: synthesis of CTM-containing peptides, CPP-conjugated degraders, POI-binding peptide constructs, and hybrid peptide-small molecule degraders
Analog library generation: focused design and synthesis of CTM variants, linker-length series, CPP alternatives, and POI-binding module modifications
Analytical characterization: confirmation of molecular identity, structural integrity, and batch-to-batch consistency for research-stage degrader evaluation
Custom synthesis integration: connection with custom PROTAC synthesis services when chimeric degrader chemistry and analog panel preparation are required
Cellular Validation and Mechanism Confirmation
CMA-based degrader activity must be separated from nonspecific peptide uptake, endosomal accumulation, lysosomal stress, or general protein turnover. We provide mechanism-focused assay systems that evaluate cellular entry, target engagement, degradation potency, lysosomal dependency, HSC70 recognition, and LAMP-2A involvement.
Cellular uptake and permeability analysis: fluorescence imaging, flow cytometry, subcellular localization, and cellular permeability assay support for degrader exposure optimization
Target degradation profiling: Western blot, capillary immunoassay, immunofluorescence, and quantitative protein detection for D_max, DC₅₀, time-course, and washout analysis
Pathway dependency studies: evaluation of lysosomal inhibition, HSC70 engagement, LAMP-2A expression, CTM-mutant controls, and proteasome-independent degradation behavior
Functional activity interpretation: integration with degradation ability assay workflows to connect molecular design with cellular degradation performance

Have You Encountered Following Challenges in CMA-Based Degrader Development?

Uncertainty about whether a selected POI is suitable for CMA-mediated lysosomal degradation
Difficulty designing a CTM that remains accessible after conjugation with the POI-binding module and CPP
Weak cellular uptake, endosomal retention, or insufficient intracellular exposure of peptide-rich degraders
Loss of target binding after linker or CTM attachment
Poor separation between true CMA engagement and nonspecific lysosomal stress
Inconsistent degradation readouts caused by cell model differences in HSC70, LAMP-2A, or lysosomal activity
Need to compare CMA-based degradation with ATTEC, AUTAC, LYTAC, or UPS-dependent degrader strategies

Tell Us Your Challenge

Contact us to discuss how we can help you overcome these hurdles

Submit Inquiry

Challenge Solving

Our Solutions for CMA-Based Degradation Development Challenges

CMA-based degrader projects require more than attaching a KFERQ-like sequence to a target binder. Productive degradation depends on target biology, degrader architecture, intracellular delivery, CTM accessibility, HSC70 recognition, LAMP-2A-dependent translocation, and correct interpretation of lysosomal pathway data. BOC Sciences provides integrated solutions that connect molecular design with mechanism-driven validation.

Solution for Target and Pathway Feasibility Many CMA projects begin with a disease-related protein but limited understanding of whether it can be productively routed to LAMP-2A. We evaluate target localization, aggregation state, degrader-accessible epitopes, cell model compatibility, HSC70/LAMP-2A expression, and assay windows. This helps clients prioritize POIs and cellular systems that are more likely to generate interpretable CMA degradation data.
Solution for CTM, CPP, and Linker Integration A strong POI binder does not guarantee a functional CMA-based degrader. The CTM must be available for HSC70 recognition, the CPP must support cellular entry, and the linker must avoid steric masking. We design focused matrices covering CTM sequence, CPP position, linker length, linker polarity, and conjugation site, then prioritize molecules based on both synthesis feasibility and expected biological performance.
Solution for CMA-Specific Assay Development Target reduction alone is not enough to prove CMA-based degradation. Our validation strategy combines POI quantification, lysosomal inhibition controls, proteasome inhibition comparison, HSC70 association, LAMP-2A dependency, CTM-mutated negative controls, and lysosomal co-localization analysis. This multi-readout workflow helps distinguish CMA engagement from nonspecific protein loss or general peptide-induced stress.
Solution for Data Interpretation and Optimization CMA-based degrader datasets often include complex relationships among dose, time, uptake, lysosomal activity, and target biology. We interpret degradation kinetics, D_max, DC₅₀, cellular exposure, pathway controls, and structure-activity trends together. This enables clients to decide whether to optimize the target binder, CTM, CPP, linker, assay timing, or cellular model.

Choose BOC Sciences to Build More Reliable CMA-Based Degrader Research Programs!

From target feasibility assessment and CMA degrader design to peptide synthesis, cellular uptake evaluation, lysosomal pathway validation, and optimization cycles, BOC Sciences provides tailored support for CMA-based targeted degradation research. Our interdisciplinary expertise helps clients reduce design uncertainty, generate interpretable data, and advance promising CMA degrader candidates with greater confidence.

Talk to Our Experts

Clients

Our CMA-Based Degradation Solutions Support Diverse R&D Organizations

Pharmaceutical Discovery Teams

Discovery teams can use CMA-based degradation research to explore lysosome-directed elimination of intracellular proteins, aggregation-prone targets, and proteins that are difficult to modulate with traditional inhibitors. BOC Sciences supports these programs with rational design, synthesis, assay development, and mechanism-focused data interpretation.

Biotechnology Companies

Biotechnology companies often need proof-of-concept data to evaluate whether CMA-based degradation can support a new target biology program. We help accelerate early decision-making through target feasibility analysis, focused degrader panel generation, pathway validation, and iterative optimization.

Academic and Translational Research Laboratories

Academic teams may use CMA-based degrader tools to study protein quality control, lysosomal biology, neurodegeneration-associated proteins, and selective autophagy mechanisms. We provide flexible design and experimental modules for exploratory and publication-oriented research.

CROs / Technical Service Platforms

CROs and technical platforms may require specialized support for peptide-based degrader design, CMA pathway assays, or lysosomal degradation analysis. BOC Sciences offers modular cooperation models that complement internal capabilities and strengthen project execution.

Get a Quote

Workflow

End-to-End CMA-Based Degradation Technology Development Workflow

01

Inquiry and Requirement Collection

Understand the client's POI, disease-relevant context, available ligand or peptide information, preferred cell model, desired degradation readouts, and project-stage objectives.

02

Target and CMA Feasibility Assessment

Evaluate target localization, binder availability, CMA pathway compatibility, HSC70/LAMP-2A context, lysosomal assay feasibility, and early technical risks.

03

Proposal Design, Scope Definition, and Quotation

Prepare a tailored research plan covering degrader design scope, analog number, synthesis strategy, assay package, data output, and optimization decision points.

04

Technical Data Transfer and Project Initiation

Receive target sequence, structural information, ligand or binder data, reference molecules, cell model details, assay protocols, and preferred evaluation endpoints.

05

CMA Degrader Design and Synthesis

Design and synthesize CMA-based degraders by combining POI-binding modules, KFERQ-like CTM sequences, CPPs, and optimized linkers.

06

In Vitro and Cell-Based Validation

Evaluate target binding, cellular uptake, lysosomal localization, degradation kinetics, dose response, time dependence, and pathway specificity.

07

Mechanism Confirmation and Optimization Iteration

Refine CTM sequence, CPP architecture, linker properties, and binder orientation based on D_max, DC₅₀, HSC70/LAMP-2A dependency, lysosomal inhibition controls, and cellular exposure.

08

Molecule Delivery and Data Reporting

Deliver molecular samples, experimental data, structure-activity interpretation, degradation profiles, pathway-control results, and recommendations for the next design cycle.

Advantages

Advantages of CMA-Based Degradation Technology

Targets the Lysosomal CMA Pathway

CMA-based degraders recruit an endogenous lysosomal pathway involving HSC70 and LAMP-2A, providing a mechanistically distinct alternative to UPS-dependent degrader technologies.

Supports Intracellular Protein Quality Control Research

CMA-based strategies are useful for studying cytosolic proteins, misfolded protein species, aggregation-prone targets, and cellular quality-control mechanisms.

Enables Modular Peptide Degrader Design

POI-binding motifs, KFERQ-like CTMs, CPPs, and linkers can be systematically modified to understand how each component influences degradation outcome.

Expands Degradation Strategy Selection

CMA-based degradation can be compared with AUTAC, ATTEC, LYTAC, and PROTAC approaches to select the most suitable modality based on cargo type, cellular location, and target biology.

Applications

Applications Supported by Our CMA-Based Degradation Platform

Neurodegeneration-Associated Protein Research

Development of CMA-based degraders for aggregation-prone proteins such as α-synuclein, mutant huntingtin, Tau-associated systems, or other disease-relevant cytosolic targets
Evaluation of degradation effects on soluble precursor species, oligomer-associated protein signals, and aggregate burden-related cellular readouts
Comparative research with PROTACs for Huntington disease and PROTACs for synucleinopathies programs when multiple degradation strategies are being considered
Analysis of lysosomal markers, HSC70 engagement, LAMP-2A dependency, and cell-state response in neuronal or neurobiology-related models

Oncology and Signaling Protein Degradation

Exploration of CMA-based degradation for intracellular oncogenic proteins, stress-response proteins, or signaling factors with available peptide or small-molecule binders
Design of CTM-containing degraders to investigate whether lysosomal routing can reduce selected POI levels in tumor cell models
Integration of target engagement, pathway dependency, and functional readouts to determine whether degradation is linked to a desired cellular response
Comparative analysis with UPS-based strategies for targets showing weak proteasomal degradation behavior

Peptide and Protein Binder-Based Degrader Research

Construction of peptide-rich CMA degraders for POIs lacking conventional small-molecule binding pockets
Optimization of CPP choice, linker composition, CTM placement, and peptide orientation to improve intracellular delivery and degradation activity
Use of fluorescence labeling, uptake quantification, and lysosomal co-localization to support early design decisions
Evaluation of peptide stability, solubility, cellular exposure, and target-binding retention during optimization

Comparative Autophagy-Based Degrader Evaluation

Side-by-side comparison of CMA-based degraders with AUTAC degradation technology development and ATTEC degradation technology development
Selection of an appropriate lysosome-directed modality based on whether the cargo is a soluble protein, aggregate-associated species, organelle component, extracellular protein, or membrane protein
Integration with pathway markers such as LC3B, p62/SQSTM1, LAMP1, HSC70, and LAMP-2A for degradation route comparison
Data-driven prioritization of CMA, macroautophagy, endosome-lysosome, or UPS-dependent degradation strategies

Case Study

Client Success Stories: CMA-Based Degradation Technology Development

Project Background

A biotechnology research team wanted to evaluate whether a CMA-based degrader could reduce mutant huntingtin-associated protein signals in a cellular model expressing an expanded polyglutamine region. The client had a polyglutamine-binding peptide candidate with measurable target engagement, but early constructs showed weak intracellular exposure and inconsistent reduction of the mutant huntingtin signal after 24 h treatment.

Our Support

BOC Sciences first analyzed the binder sequence, CTM position, charge distribution, and predicted linker accessibility. We designed 26 CMA degrader constructs combining three KFERQ-like CTM variants, two CPP formats, and PEG or semi-rigid linkers ranging from 6 to 15 atoms. The first screening round identified that N-terminal CTM placement improved HSC70 association but reduced cellular uptake, while a C-terminal CPP with a mid-length PEG linker produced stronger intracellular exposure. We then selected eight second-round analogs and evaluated target reduction at 6 h, 24 h, and 48 h, together with lysosomal inhibition and CTM-mutated controls. The best construct showed a clearer time-dependent mutant huntingtin signal decrease, retained target engagement, and displayed stronger lysosome-associated co-localization than the initial design.

Client Testimonial

BOC Sciences helped us convert a broad CMA degrader concept into a structured design and validation workflow. Their ability to connect peptide architecture, intracellular delivery, and pathway-specific controls gave us a clear direction for our next optimization cycle.

Project Background

A pharmaceutical discovery group had synthesized several α-synuclein-targeting CMA degrader prototypes, but the observed protein reduction varied strongly across cell models. The client needed to determine whether the weak response was caused by insufficient target binding, poor CTM exposure, limited cellular uptake, or low CMA pathway activity.

Our Support

We redesigned the evaluation workflow by pairing target-binding analysis with cellular uptake imaging, HSC70 pull-down, LAMP-2A expression profiling, lysosomal inhibition studies, and CTM-mutant negative controls. The first analysis showed that two prototypes entered cells efficiently but accumulated in punctate endosomal compartments, while another showed target binding but weak HSC70 association. Based on these data, we generated 18 optimized analogs with altered CPP placement, shorter hydrophilic linkers, and more exposed CTM positioning. The prioritized analogs produced stronger HSC70-associated signal, improved lysosomal co-localization, and more consistent α-synuclein reduction over a 24–48 h evaluation window. The client received a refined structure-CMA activity relationship map and a practical template for further degrader design.

Client Testimonial

The BOC Sciences team helped us understand why our first CMA degrader series was difficult to interpret. Their multi-readout strategy separated uptake problems from CMA engagement problems and allowed us to focus our chemistry resources more effectively.

Why Us

Why Choose BOC Sciences for Your CMA-Based Degradation Project?

Integrated CMA Degrader Development Support

We provide coordinated support across target assessment, POI-binding module design, CTM engineering, CPP optimization, synthesis, cellular validation, and iterative optimization.

Deep Lysosome-Based Degrader Expertise

Our team understands the design logic of CMA, AUTAC, ATTEC, LYTAC, and related lysosome-directed degradation technologies, helping clients choose the right strategy for each target.

Mechanism-Focused Validation

We design studies that connect POI reduction with HSC70 recognition, LAMP-2A dependency, lysosomal involvement, CTM control molecules, and cellular uptake data.

Flexible Modular Service Models

Clients can access individual modules, such as CTM design or cellular validation, or request end-to-end CMA-based degrader development from concept to optimized analog series.

Data-Driven Design Iteration

We connect chemistry, peptide design, cellular uptake, pathway biology, and degradation data to refine degrader architecture through rational optimization cycles.

Clear Reporting and Decision Support

We provide organized experimental data, practical interpretation, and clear recommendations to support the next stage of CMA degrader design, screening, or validation.

Frequently Asked Questions (FAQ)

Frequently Asked Questions

Still have questions?

Contact Us

What is CMA-Based Degradation Technology?

CMA-Based Degradation Technology is a targeted protein degradation strategy that uses the Chaperone-Mediated Autophagy (CMA) pathway to remove selected proteins. Its core concept is to design a degrader that links a protein of interest (POI) to a CMA-recognition motif similar to the natural KFERQ sequence. This allows the complex to be recognized by heat shock cognate 71 kDa protein (HSC70), delivered to lysosome-associated membrane protein type 2A (LAMP-2A), translocated into the lysosomal lumen, and degraded by lysosomal enzymes. This approach provides a new research strategy for proteins that are difficult to address using conventional inhibitors or ubiquitin-proteasome system-based degradation methods.

What are structural features of CMA degraders?

Chaperone-Mediated Autophagy degraders usually have a modular structure composed of three main parts: a targeting ligand or peptide that specifically recognizes the POI, a CMA-targeting motif that mimics the natural KFERQ sequence and enables recognition by HSC70, and a Cell-Penetrating Peptide (CPP) that helps the molecule enter cells. The linker is also a critical structural element, as its length, flexibility, polarity, and conjugation site can influence POI binding, CMA motif exposure, HSC70 recruitment, cellular uptake, and lysosomal delivery. Therefore, CMA degrader design is not a simple combination of peptide segments, but a systematic optimization process balancing target recognition, intracellular entry, chaperone recognition, and pathway-specific degradation.

Which targets are suitable for CMA-Based Degradation?

CMA-Based Degradation is generally suitable for intracellular proteins that are accessible to designed degraders, can be recognized by a specific ligand or peptide binder, and are theoretically compatible with CMA-mediated lysosomal delivery. It is especially valuable for research involving neurodegeneration-associated proteins, misfolded proteins, aggregation-prone proteins, certain oncology-related signaling proteins, and targets that are difficult to regulate with conventional small-molecule inhibitors. Early project assessment usually includes POI localization, conformational state, binder availability, HSC70/LAMP-2A expression in the selected cell model, and the feasibility of establishing reliable degradation readouts.

How can CMA degradation be validated experimentally?

CMA degradation should not be validated only by observing a decrease in target protein level. A more reliable strategy requires multiple lines of mechanistic evidence, including dose- and time-dependent target reduction, comparison with CMA-targeting motif mutant controls, evaluation of HSC70 binding, analysis of LAMP-2A dependency, lysosomal co-localization, and pathway-specific studies related to lysosomal degradation. It is also important to exclude nonspecific cytotoxicity, reduced protein expression, general autophagy activation, or proteasome-mediated degradation. BOC Sciences can help clients establish an integrated evaluation workflow covering cellular uptake, target engagement, pathway validation, degradation analysis, and data interpretation.

How does CMA degradation differ from PROTAC?

The main difference between CMA-Based Degradation and PROTAC lies in the cellular degradation pathway they use. PROTAC typically recruits an E3 ubiquitin ligase to label the target protein for proteasomal degradation, while a CMA-based degrader relies on HSC70 recognition of a KFERQ-like motif and LAMP-2A-mediated translocation into lysosomes. Therefore, CMA technology is more closely associated with selective lysosomal degradation and is particularly useful for exploring intracellular proteins that may be poorly responsive to proteasomal degradation, including certain misfolded or aggregation-prone proteins.